(NASDAQ: IRD) Opus Genetics's forecast annual revenue growth rate of 45.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.77%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Opus Genetics's revenue in 2025 is $13,651,000.On average, 1 Wall Street analysts forecast IRD's revenue for 2025 to be $934,294,345, with the lowest IRD revenue forecast at $934,294,345, and the highest IRD revenue forecast at $934,294,345. On average, 1 Wall Street analysts forecast IRD's revenue for 2026 to be $1,519,570,688, with the lowest IRD revenue forecast at $1,519,570,688, and the highest IRD revenue forecast at $1,519,570,688.
In 2027, IRD is forecast to generate $2,560,061,963 in revenue, with the lowest revenue forecast at $2,560,061,963 and the highest revenue forecast at $2,560,061,963.